<DOC>
	<DOC>NCT02668640</DOC>
	<brief_summary>The study is a non-interventional, observational study is to assess the effect of Adalimumab on health-related quality of life and work productivity in patients with Rheumatoid Arthritis (RA) in China.</brief_summary>
	<brief_title>Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in China</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Participant has a diagnosis of RA as defined by the 1987 revised American College of Rheumatology (ACR) classification criteria and/or the ACR/the European League against Rheumatism (EULAR) 2010 classification criteria (any duration since diagnosis). Participants with moderate to severe RA defined as Disease Activity Score in 28 Joints (DAS28) Erythrocyte Sedimentation Rate (ESR) or DAS28 CReactive Protein (CRP) &gt;3.2 Biologically treatment na√Øve and initiated adalimumab at baseline visit, as per standard daily clinical practice. Availability of clinical data of the previous 12 weeks prior to week 0 (baseline). Ability to selfcomplete patient questionnaires. Participants have signed the authorization (or informed consent where applicable) to disclose and use personal health information after been prescribed with adalimumab. Participants who are pregnant or breast feeding at enrolment or wish to become pregnant in the next 24 weeks. Participation in any RArelated clinical trial at the time of enrolment, at baseline or at any point during the past 24 weeks prior to baseline Participants, who in the clinician's view, may not be able to accurately report their quality of life (QoL) or prior resource utilization Participants, who in the clinician's view, may not be able to adhere to Adalimumab therapy over 24 weeks.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Work productivity</keyword>
	<keyword>Rheumatoid arthritis (RA)</keyword>
	<keyword>Adalimumab</keyword>
	<keyword>Quality of life (QOL)</keyword>
</DOC>